Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CORT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.96B
- P/E (TTM)
- 47.83
- Forward P/E
- 12.77
- EPS (TTM)
- $1.33
- Dividend yield
- None
- 52-week range
- 28.66 – 126.38
- Day range
- 62.81 – 65.13
- Volume / Avg
- 1.09M / 1.26M
- Beta
- —
- Shares outstanding
- 109.44M
52-week range
CORT stock today
On Nov 20, CORT ended the session at $63.62, shedding $1.36 (2.09%), versus the S&P 500's 3.70% decline. At this level, CORT sits in the middle of its 52-week range of $28.66 to $126.38: 49.7% below the high, set on Aug 25, 2026 and 122.0% above the low. CORT is up 82.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.7%.
Corcept Therapeutics trades at 47.8x its trailing twelve-month earnings per share of $1.33. Its forward P/E of 12.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Corcept Therapeutics
Company profileCorcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Joseph K. Belanoff M.D.
- Headquarters
- Redwood City, CA
- Employees
- 730
- IPO year
- 2004
- Website
- corcept.com
Financial highlights
Full financialsIn fiscal 2025, Corcept Therapeutics generated $761.4 million in revenue, up 12.8% from fiscal 2024, its 13th consecutive year of revenue growth. Net income was $99.7 million (-29.4% year over year), for a net margin of 13.1% versus a median of 25.2% in the prior 5 years. Gross margin was 98.3% (down from 98.4%) and operating margin 5.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M |
| Growth | +12.79% | +39.94% | +20.04% | +9.80% | +3.42% |
| Net income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$142.60+124.14%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $1.01 vs $0.68
- Surprise
- +48.53%
CORT news
All CORT news- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesNasdaqCORT, TGTX, TARS
- Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 millionNasdaqCORT, BRK.A
- Corcept Therapeutics GAAP EPS of $1.01 beats by $0.22, revenue of $340.5M beats by $4.12MSeeking Alpha
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate UpdateBusiness Wire
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire
- Corcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian CancerNasdaq
- Why is Corcept Therapeutics stock rallying today?Investing.com
- Corcept Therapeutics plunges 20% on Genmab cancer dataSeeking Alpha
Corcept Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs CORT |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs CORT |
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs CORT |
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs CORT |
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs CORT |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs CORT |
| MIRMMirum Pharmaceuticals Inc. | 96.13 | +0.65% | $6.28B | vs CORT |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs CORT |
Indexes, lists and sector
Corcept Therapeutics stock FAQ
What is Corcept Therapeutics's stock price today?
CORT last traded at $63.62 as of Nov 20, 4:00 PM EST, down 2.09% on the day. Prices are delayed at least 15 minutes.
What is CORT's P/E ratio?
CORT trades at a trailing P/E ratio of 47.83 and a forward P/E of 12.77.
Who is Corcept Therapeutics's CEO?
Dr. Joseph K. Belanoff M.D. is the chief executive officer of Corcept Therapeutics Incorporated, which has about 730 employees.
What is the CORT 52-week high?
The 52-week high for CORT is $126.38 and the 52-week low is $28.66. The stock is currently 49.7% below its high.